Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now

Coherus BioSciences Inc

$0.92

+$0.03 (+3.37%) Day

1 day chart

Created with Highcharts 11.1.0
10:0011:0012:0013:0014:0015:0016:00
0.8750.90.9250.950.97511.025
Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About CHRS

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.

Market Capitalisation

$106.63M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

2.07M

High today

$1.00

Low today

$0.90

Open price

$0.90

52-week high

$2.64

52-week low

$0.66

Ready to start your investing journey with Stake?

Open an account

CHRS FAQs

  1. Find the right investing platform for you. To buy CHRS shares in Australia, you’ll need to open an account with an investing platform that offers the security. Try Stake, you can sign up in minutes.
  2. Fund your brokerage account. Once you are set up you can deposit into your account with different payment methods.
  3. Search for CHRS or Coherus BioSciences Inc. Find the stock by using the search function and go to the CHRS page.
  4. Place an order to buy CHRS. Press the ‘Buy’ button and choose an order type to place your trade. Depending on the order type, the trade will go through straight away or when a price target is hit.
  5. Monitor your portfolio. You’ve now purchased some CHRS shares. Stay on top of your portfolio and monitor its performance. You may be eligible for dividends and shareholder voting rights that affect your stock.

The ticker symbol for Coherus BioSciences Inc is CHRS.

One share of CHRS is valued at $0.92 as of 16 March 2025.

As of 16 March 2025 Coherus BioSciences Inc has a market cap of $106.63M.

CHRS stock is currently -20.69% over the last month. Whether or not CHRS is a good buy depends on your investing goals and strategy. It's essential to conduct thorough research on Coherus BioSciences Inc to see if it suits your investment portfolio.

The Price to Earnings ratio of CHRS is 4.84.

The Earnings Per Share of CHRS is $0.18.

The Coherus BioSciences Inc 52-week high stock price is $2.64.

The Coherus BioSciences Inc 52-week low stock price is $0.66.

Yes, the Stake investing platform allows you to buy CHRS shares and over 9,500 more stocks and ETFs on Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in CHRS
on Stake

Buy CHRS from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of CHRS from only US$10 with fractional shares

Get started
Canstar award phone
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
CHRS related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd is registered as an overseas company in New Zealand (NZBN: 9429047452152), and is registered as a Financial Service Provider under the Financial Service Providers (Registration and Dispute Resolution) Act 2008 (No. FSP774414). We hold a full licence issued by the Financial Markets Authority to provide a financial advice service under the Financial Markets Conduct Act 2013. However, the content on this website has not been prepared to take into account any of your individual objectives, financial situation or needs. To the extent you require further information about the relevant New Zealand legislation that may apply, or require specific advice, please contact your legal and/or financial adviser (as appropriate). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Terms & Conditions, Privacy Policy, Financial Advice Disclosure and Disclaimers before deciding to use or invest on Stake. By using the Stake website or service in any way, you agree to our Privacy Policy and Terms & Conditions All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake is a registered trademark under class 36 (New Zealand).

Copyright © 2025 Stake. All rights reserved.

This site uses cookies. By using our site you agree to the Stake Privacy Policy.